Company Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted conditioning therapies for hematopoietic stem cell transplantation (HSCT), gene therapy, and treatment of severe autoimmune diseases. The company operates within the biotechnology and immunology sectors, with a primary emphasis on reducing the toxicity associated with traditional transplant conditioning regimens such as chemotherapy and radiation. Its lead product candidate, briquilimab (formerly JSP191), is an engineered monoclonal antibody that targets the CD117 (c-Kit) receptor on hematopoietic stem cells. Jasper Therapeutics’ development programs are aimed at enabling safer stem cell replacement and gene-editing procedures for patients with rare diseases, bone marrow failure syndromes, and immune-mediated conditions.

The company’s core revenue profile remains development-stage oriented, with operations primarily supported through equity financing, strategic collaborations, and capital market activity rather than commercial product sales. Jasper Therapeutics evolved through a merger involving Amplitude Healthcare Acquisition Corporation and legacy Jasper Therapeutics in 2021, after which it became publicly traded on Nasdaq under the ticker JSPR. The company has positioned itself within the emerging field of targeted conditioning biology, seeking to differentiate its platform through reduced toxicity, outpatient treatment potential, and broader applicability across transplant and gene therapy settings.

Business Operations

Jasper Therapeutics primarily operates as a single-segment biotechnology enterprise centered on the research and clinical development of antibody-based conditioning agents. Its principal asset, briquilimab, is being evaluated in multiple clinical settings, including severe combined immunodeficiency (SCID), chronic spontaneous urticaria, sickle cell disease, Fanconi anemia, and other stem-cell-related disorders. The company’s business model is based on advancing internally developed biologic candidates through clinical development with the long-term objective of commercialization or strategic partnering.

Operations are concentrated in the United States, though the company participates in global clinical development activities through collaborations with research institutions, clinical trial centers, and contract research organizations. Jasper Therapeutics relies on outsourced manufacturing and development infrastructure typical of clinical-stage biotechnology companies. The company controls intellectual property related to CD117-targeting antibodies and conditioning approaches designed to replace conventional myeloablative regimens. Public disclosures identify collaborations and clinical relationships with transplant centers and academic institutions, though publicly available information does not indicate the presence of large-scale commercial joint ventures or diversified operating subsidiaries. Data inconclusive based on available public sources regarding material revenue-generating partnerships.

Strategic Position & Investments

Jasper Therapeutics’ strategic direction is centered on expanding the use of targeted conditioning in stem cell transplantation and gene therapy. The company has focused investment toward advancing clinical trials for briquilimab, particularly in diseases where safer conditioning could improve patient eligibility and treatment outcomes. Its strategy aligns with broader industry interest in reducing treatment-related toxicity in gene-editing and cell-therapy procedures. The company has emphasized opportunities in rare diseases and immunologic conditions where targeted depletion of stem cells or mast cells may provide therapeutic benefit.

The company has also pursued indications beyond transplant conditioning, including mast-cell-driven diseases such as chronic spontaneous urticaria, reflecting an effort to broaden the commercial applicability of its platform. Jasper Therapeutics has raised capital through public offerings and financing transactions to support research and development activities. Public filings and investor materials indicate ongoing investment in clinical expansion, manufacturing readiness, and regulatory advancement. No major acquisitions or diversified portfolio holdings have been prominently disclosed in public filings as of available reporting periods.

Geographic Footprint

Jasper Therapeutics is headquartered in the United States, with principal operations based in California. Its clinical development activities primarily focus on North American markets, although the company engages with international clinical research networks and healthcare institutions as part of multicenter studies. The company’s operational footprint remains relatively concentrated compared with large multinational pharmaceutical companies, reflecting its status as a clinical-stage biotechnology organization.

The company’s market relevance extends into broader global sectors including gene therapy, rare disease treatment, and stem cell transplantation, areas with active research and investment across North America, Europe, and parts of Asia-Pacific. While Jasper Therapeutics does not currently maintain a large commercial international infrastructure, its therapeutic programs are intended for diseases with global patient populations and potential future international regulatory pathways.

Leadership & Governance

Jasper Therapeutics is led by an executive team with experience in biotechnology development, immunology, clinical medicine, and capital markets. Company leadership has consistently emphasized precision conditioning approaches designed to improve safety and expand access to stem cell transplantation and gene-editing therapies. Governance and operational strategy are guided through oversight structures typical of publicly traded biotechnology companies, including board-level review of clinical, financial, and regulatory priorities.

Key executives publicly associated with the company include:

• Ron Martell – Executive Chairman
• Meghan G. Hedtke – Chief Operating Officer
• Jennifer Herron – Chief Financial Officer
• Dr. Leslie Meltzer – Chief Medical Officer
• Dr. Robert Peter Gale – Scientific and medical leadership advisor roles reported in company materials

Public filings, including SEC filings, investor presentations, and corporate governance disclosures, indicate leadership focus on advancing late-stage clinical development, regulatory engagement, and strategic financing to support long-term commercialization objectives. Some executive appointments and board compositions have changed over time; data reflects publicly available information from recent reporting periods.